Effects or Symptoms > HAMA
(human anti-mouse antibodies)
Reference | Resources & Research News
Antibodies. A mouse antibody administered to a human is seen by the
human immune system as a foreign protein (antigen). The human immune system
then generates its own human antibodies against
the introduced mouse antibody (the HAMA response).
The HAMA response can create problems such as allergic-like reaction
to the mouse antibody, rapid removal of the mouse antibody, and weak
ability to recruit human immune system processes necessary to clear
the targeted antigen (e.g. tumor cell).
The first may generate additional health problems in a patient while
the latter two reduce the efficacy of the mouse antibody as a
therapeutic. - Genentech gene.com
"Patients receiving murine antibodies, particularly in high amounts, may form human antibodies against these foreign proteins or human antimouse antibodies (HAMA), which usually occur within 2–3 wk after the first mAb administration and within hours or days after a repeated administration.
Even after repeated mAb administrations, HAMA formation usually does not cause significant adverse reactions, although flu-like symptoms or mild-to-moderate anaphylactic reactions (e.g., urticaria, bronchospasm) may occur, which are easily treatable with antihistamines or corticosteroids
* Wahl RL, Zasadny KR, Estes J, et al. Single center experience with iodine I131
tositumomab radioimmunotherapy for previously untreated follicular lymphoma
(FL) [abstract]. J Nucl Med. 2000;41(suppl):79P.
HAMA as a Side Effect of Treatment
one-third of patients with relapsed B-cell malignancies develop
anti-mouse antibody (HAMA) following mouse antibody treatment"
- Survival benefit associated with human anti-mouse antibody
(HAMA) in patients with B-cell malignancies - springerlink.com
approximately 10% of patients treated with tositumomab and
iodine I 131 tositumomab (bexxar) developed
human-anti-mouse antibodies, treatment with tositumomab
does not preclude the administration of subsequent
chimeric (mouse-human) antibody therapies."
- A clinical and scientific overview of tositumomab and
iodine I 131 tositumomab.
Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. Review. PMID: 12728404
If a person makes HAMA, they
could have a serious allergic reaction to any other drug
diagnostic test that was made from mouse protein, or it could
affect how well the drug or
diagnostic test worked.
Bexxar for NHL - http://www.bexxar.com/patients/bexxar_patientsmain.html
Does Development of HAMA After Tositumomab (Bexxar) Preclude
With Rituximab (Rituxan)? -
Development of HAMA can occur after exposure to tositumomab,
especially in patients who have not received prior chemotherapy
for their disease.
In this group who receive "front-line" tositumomab, HAMA
antibodies have been demonstrated in as many as 64%. In a study by
Mark S. Kaminski, from the University of Michigan, Ann
Arbor, Michigan, and colleagues, 22 patients with HAMA responses to
tositumomab were studied, and 6 were found to have high titer (> 500 mg/mL)
Thirteen of these patients subsequently received rituximab.
Although response rates were
not reported, it is important to note that there was no evidence
of increased severity or frequency of infusion reactions. Therefore, it seems that rituximab can be
given safely after developmentof HAMA responses to tositumomab.
- Alexandra M. Levine, MD Robert S.
Rituximab, Tositumomab (Bexxar), Ibritumomab (Zevalin): And the
(free login req.)
& Research News:
Survival benefit associated
with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 2006
Dec;55(12):1451-8. Epub 2006 Feb 22. PMID:
Patients with B-cell malignancies that developed high HAMA
titers had longer survival that was not explained by risk factors or histologic grade,
suggesting the importance of the immune system.